Intercept Pharmaceuticals Inc EBITDA margin
What is the EBITDA margin of Intercept Pharmaceuticals Inc?
The EBITDA margin of Intercept Pharmaceuticals Inc is -29.95%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to Intercept Pharmaceuticals Inc
What does Intercept Pharmaceuticals Inc do?
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Companies with ebitda margin similar to Intercept Pharmaceuticals Inc
- Starcom Plc has EBITDA margin of -30.13%
- Aban Offshore has EBITDA margin of -30.08%
- Bever NV has EBITDA margin of -30.07%
- East 33 Ltd has EBITDA margin of -30.02%
- Symphony Environmental Technologies Plc has EBITDA margin of -30.00%
- InnoCare Pharma has EBITDA margin of -29.99%
- Intercept Pharmaceuticals Inc has EBITDA margin of -29.95%
- Jimu has EBITDA margin of -29.92%
- Zip Co has EBITDA margin of -29.92%
- BlackRock Muni Fund II Inc has EBITDA margin of -29.91%
- McEwen Mining has EBITDA margin of -29.77%
- K2 Asset Management Ltd has EBITDA margin of -29.76%
- Greenrose Acquisition has EBITDA margin of -29.72%